Early clinical markers of aggressive multiple sclerosis.


Journal

Brain : a journal of neurology
ISSN: 1460-2156
Titre abrégé: Brain
Pays: England
ID NLM: 0372537

Informations de publication

Date de publication:
01 05 2020
Historique:
received: 22 08 2019
revised: 21 01 2020
accepted: 05 02 2020
pubmed: 10 5 2020
medline: 15 12 2020
entrez: 10 5 2020
Statut: ppublish

Résumé

Patients with the 'aggressive' form of multiple sclerosis accrue disability at an accelerated rate, typically reaching Expanded Disability Status Score (EDSS) ≥ 6 within 10 years of symptom onset. Several clinicodemographic factors have been associated with aggressive multiple sclerosis, but less research has focused on clinical markers that are present in the first year of disease. The development of early predictive models of aggressive multiple sclerosis is essential to optimize treatment in this multiple sclerosis subtype. We evaluated whether patients who will develop aggressive multiple sclerosis can be identified based on early clinical markers. We then replicated this analysis in an independent cohort. Patient data were obtained from the MSBase observational study. Inclusion criteria were (i) first recorded disability score (EDSS) within 12 months of symptom onset; (ii) at least two recorded EDSS scores; and (iii) at least 10 years of observation time, based on time of last recorded EDSS score. Patients were classified as having 'aggressive multiple sclerosis' if all of the following criteria were met: (i) EDSS ≥ 6 reached within 10 years of symptom onset; (ii) EDSS ≥ 6 confirmed and sustained over ≥6 months; and (iii) EDSS ≥ 6 sustained until the end of follow-up. Clinical predictors included patient variables (sex, age at onset, baseline EDSS, disease duration at first visit) and recorded relapses in the first 12 months since disease onset (count, pyramidal signs, bowel-bladder symptoms, cerebellar signs, incomplete relapse recovery, steroid administration, hospitalization). Predictors were evaluated using Bayesian model averaging. Independent validation was performed using data from the Swedish Multiple Sclerosis Registry. Of the 2403 patients identified, 145 were classified as having aggressive multiple sclerosis (6%). Bayesian model averaging identified three statistical predictors: age > 35 at symptom onset, EDSS ≥ 3 in the first year, and the presence of pyramidal signs in the first year. This model significantly predicted aggressive multiple sclerosis [area under the curve (AUC) = 0.80, 95% confidence intervals (CIs): 0.75, 0.84, positive predictive value = 0.15, negative predictive value = 0.98]. The presence of all three signs was strongly predictive, with 32% of such patients meeting aggressive disease criteria. The absence of all three signs was associated with a 1.4% risk. Of the 556 eligible patients in the Swedish Multiple Sclerosis Registry cohort, 34 (6%) met criteria for aggressive multiple sclerosis. The combination of all three signs was also predictive in this cohort (AUC = 0.75, 95% CIs: 0.66, 0.84, positive predictive value = 0.15, negative predictive value = 0.97). Taken together, these findings suggest that older age at symptom onset, greater disability during the first year, and pyramidal signs in the first year are early indicators of aggressive multiple sclerosis.

Identifiants

pubmed: 32386427
pii: 5835340
doi: 10.1093/brain/awaa081
doi:

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1400-1413

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : CommentIn

Informations de copyright

© The Author(s) (2020). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Auteurs

Charles B Malpas (CB)

CORe Unit, Department of Medicine, University of Melbourne, Melbourne, Australia.
Department of Neurology, Royal Melbourne Hospital, Melbourne, Australia.

Ali Manouchehrinia (A)

Centre for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden.

Sifat Sharmin (S)

CORe Unit, Department of Medicine, University of Melbourne, Melbourne, Australia.
Department of Neurology, Royal Melbourne Hospital, Melbourne, Australia.

Izanne Roos (I)

CORe Unit, Department of Medicine, University of Melbourne, Melbourne, Australia.
Department of Neurology, Royal Melbourne Hospital, Melbourne, Australia.

Dana Horakova (D)

Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic.

Eva Kubala Havrdova (EK)

Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic.

Maria Trojano (M)

Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari, Bari, Italy.

Guillermo Izquierdo (G)

Hospital Universitario Virgen Macarena, Sevilla, Spain.

Sara Eichau (S)

Hospital Universitario Virgen Macarena, Sevilla, Spain.

Roberto Bergamaschi (R)

IRCCS Mondino Foundation, Pavia, Italy.

Patrizia Sola (P)

Department of Neuroscience, Azienda Ospedaliera Universitaria, Modena, Italy.

Diana Ferraro (D)

Department of Neuroscience, Azienda Ospedaliera Universitaria, Modena, Italy.
Department of Biomedical, Metabolic and Neurosciences, University of Modena and Reggio Emilia, Modena, Italy.

Alessandra Lugaresi (A)

Department of Biomedical and Neuromotor Science, University of Bologna, Bologna, Italy.
IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.

Alexandre Prat (A)

CHUM and Universite de Montreal, Montreal, Canada.

Marc Girard (M)

CHUM and Universite de Montreal, Montreal, Canada.

Pierre Duquette (P)

CHUM and Universite de Montreal, Montreal, Canada.

Pierre Grammond (P)

CISSS de Chaudière-Appalaches, Levis, Canada.

Francois Grand'Maison (F)

Neuro Rive-Sud, Quebec, Canada.

Serkan Ozakbas (S)

Dokuz Eylul University, Konak/Izmir, Turkey.

Vincent Van Pesch (V)

Cliniques Universitaires Saint-Luc, Brussels, Belgium.
Université Catholique de Louvain, Brussels, Belgium.

Franco Granella (F)

Department of Medicine and Surgery, University of Parma, Parma, Italy.

Raymond Hupperts (R)

Zuyderland Ziekenhuis, Sittard, The Netherlands.

Eugenio Pucci (E)

UOC Neurologia, Azienda Sanitaria Unica Regionale Marche - AV3, Macerata, Italy.

Cavit Boz (C)

KTU Medical Faculty Farabi Hospital, Trabzon, Turkey.

Youssef Sidhom (Y)

Department of Neurology, Razi Hospital, Manouba, Tunisia.

Riadh Gouider (R)

Department of Neurology, Razi Hospital, LR 18SP03, Clinical Investigation Center Neurosciences and Mental Health, Faculty of Medicine University Tunis El Manar, Tunis, Tunisia.

Daniele Spitaleri (D)

Azienda Ospedaliera di Rilievo Nazionale San Giuseppe Moscati Avellino, Avellino, Italy.

Aysun Soysal (A)

Bakirkoy Education and Research Hospital for Psychiatric and Neurological Diseases, Istanbul, Turkey.

Thor Petersen (T)

Kommunehospitalet, Arhus C, Denmark.

Freek Verheul (F)

Groene Hart Ziekenhuis, Gouda, The Netherlands.

Rana Karabudak (R)

Hacettepe University, Ankara, Turkey.

Recai Turkoglu (R)

Haydarpasa Numune Training and Research Hospital, Istanbul, Turkey.

Cristina Ramo-Tello (C)

Hospital Germans Trias i Pujol, Badalona, Spain.

Murat Terzi (M)

Medical Faculty, 19 Mayis University, Samsun, Turkey.

Edgardo Cristiano (E)

Hospital Italiano, Buenos Aires, Argentina.

Mark Slee (M)

Flinders University, Adelaide, Australia.

Pamela McCombe (P)

University of Queensland, Brisbane, Australia.
Royal Brisbane and Women's Hospital, Brisbane, Australia.

Richard Macdonell (R)

Austin Health, Melbourne, Australia.

Yara Fragoso (Y)

Universidade Metropolitana de Santos, Santos, Brazil.

Javier Olascoaga (J)

Instituto de Investigación Sanitaria Biodonostia, Hospital Universitario Donostia, San Sebastián, Spain.

Ayse Altintas (A)

Koc University, School of Medicine, Department of Neurology, Istanbul, Turkey.

Tomas Olsson (T)

Department of Clinical Neuroscience, Karolinska Institutet, Sweden.

Helmut Butzkueven (H)

Central Clinical School, Monash University, Melbourne, Australia.
Department of Neurology, The Alfred Hospital, Melbourne, Australia.
Department of Neurology, Box Hill Hospital, Monash University, Melbourne, Australia.

Jan Hillert (J)

Department of Clinical Neuroscience, Karolinska Institutet, Sweden.

Tomas Kalincik (T)

CORe Unit, Department of Medicine, University of Melbourne, Melbourne, Australia.
Department of Neurology, Royal Melbourne Hospital, Melbourne, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH